Veraxa Biotech (VRXA) interim CFO discloses zero share ownership

Rhea-AI Filing Summary

Veraxa Biotech Holding AG (VRXA) filed an initial statement of beneficial ownership (Form 3) for reporting person Carl von Halem, who serves as Interim CFO. The filing does not report any equity transactions or holdings, and no Rule 10b5-1 trading plan is indicated.

Key Terms

Form 3, beneficial ownership, Rule 10b5-1

3 terms

Form 3 regulatory

"filed an initial statement of beneficial ownership (Form 3) for reporting"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"filed an initial statement of beneficial ownership (Form 3) for"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Rule 10b5-1 regulatory

"no Rule 10b5-1 trading plan is indicated"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

Who is the reporting person in the VRXA Form 3 filing?

The reporting person is Carl von Halem, who is identified as the Interim CFO of Veraxa Biotech Holding AG (VRXA) in this Form 3 initial statement of beneficial ownership.

Does the VRXA Form 3 report any share transactions by Carl von Halem?

No. The Form 3 for Veraxa Biotech Holding AG (VRXA) reports no share transactions for Carl von Halem; all buy, sell, acquire, dispose, and other transaction counts are shown as zero.

Are any equity holdings reported for Carl von Halem in VRXA?

No equity holdings are reported. The Form 3 summary shows zero holding entries and no derivative positions for Carl von Halem with respect to Veraxa Biotech Holding AG (VRXA).

Is there any Rule 10b5-1 trading plan disclosed in the VRXA Form 3?

No. The Form 3 data for Veraxa Biotech Holding AG (VRXA) shows the Rule 10b5-1 trading plan field as null, and no footnote indicates that trades were made under such a plan.

What insider trading direction is indicated in this VRXA Form 3?

None. The transaction summary for Veraxa Biotech Holding AG (VRXA) shows netBuySellDirection as neutral and zero transactions of any type, so no buy or sell direction is indicated.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/20/2026 - 04:00 PM Accepted by SEC EDGAR 08/20/2026 - 04:00 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

von Halem Carl

(Last) (First) (Middle)

TALACKER 35

(Street)

ZURICH V8 8001

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/10/2026

3. Issuer Name and Ticker or Trading Symbol
Veraxa Biotech AG - Post de-SPAC [ VRXA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CFO

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Carl von Halem	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)